Literature DB >> 27071966

Novel insight into the dangerous connection between diabetes and heart failure.

C Lombardi1, V Spigoni2, E Gorga2, A Dei Cas3.   

Abstract

Heart failure (HF) affects approximately 1-2 % of the adult population. Diabetes mellitus (DM) is one of the most frequent comorbidities in HF, portending a worse prognosis. DM is associated with an increased risk of artery disease, and consequently of post-ischemic HF, but it may also alter directly the myocardial structure and function. Insights into the pathophysiological mechanisms of diabetic cardiomyopathy have been provided by both experimental and clinical investigations. In recent years, it has emerged that the fibrotic process is a result of the convergence of multiple neurohormonal alterations in diabetic cardiomyopathy at the basis of disease progression and phenotype determination: HF with reduced or preserved ejection fraction. Therapies for HF and DM should demonstrate an improved prognosis and have a neutral effect on glucose homeostasis and the risk of HF development.

Entities:  

Keywords:  Diabetes mellitus; Diabetic cardiomyopathy; Fibrosis; Heart failure; Therapy

Mesh:

Year:  2016        PMID: 27071966     DOI: 10.1007/s00059-016-4415-7

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  72 in total

Review 1.  Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia.

Authors:  Razi Khan; Richard Sheppard
Journal:  Immunology       Date:  2006-05       Impact factor: 7.397

2.  Eplerenone in patients with systolic heart failure and mild symptoms.

Authors:  Faiez Zannad; John J V McMurray; Henry Krum; Dirk J van Veldhuisen; Karl Swedberg; Harry Shi; John Vincent; Stuart J Pocock; Bertram Pitt
Journal:  N Engl J Med       Date:  2010-11-14       Impact factor: 91.245

3.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

Authors:  Benjamin M Scirica; Deepak L Bhatt; Eugene Braunwald; P Gabriel Steg; Jaime Davidson; Boaz Hirshberg; Peter Ohman; Robert Frederich; Stephen D Wiviott; Elaine B Hoffman; Matthew A Cavender; Jacob A Udell; Nihar R Desai; Ofri Mosenzon; Darren K McGuire; Kausik K Ray; Lawrence A Leiter; Itamar Raz
Journal:  N Engl J Med       Date:  2013-09-02       Impact factor: 91.245

4.  Effect of eplerenone versus spironolactone on cortisol and hemoglobin A₁(c) levels in patients with chronic heart failure.

Authors:  Masayuki Yamaji; Takayoshi Tsutamoto; Chiho Kawahara; Keizo Nishiyama; Takashi Yamamoto; Masanori Fujii; Minoru Horie
Journal:  Am Heart J       Date:  2010-11       Impact factor: 4.749

5.  Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF.

Authors:  Prakash C Deedwania; Thomas D Giles; Michael Klibaner; Jalal K Ghali; Johan Herlitz; Per Hildebrandt; John Kjekshus; Jindrich Spinar; Jiri Vitovec; Hilary Stanbrook; John Wikstrand
Journal:  Am Heart J       Date:  2005-01       Impact factor: 4.749

6.  Improved insulin sensitivity by the angiotensin receptor antagonist irbesartan in patients with systolic heart failure: a randomized double-blinded placebo-controlled study.

Authors:  Wolfram Doehner; Johanna Todorovic; Cornelia Kennecke; Mathias Rauchhaus; Anja Sandek; Mitja Lainscak; Sophie van Linthout; Carsten Tschöpe; Stephan von Haehling; Stefan D Anker
Journal:  Int J Cardiol       Date:  2012-11-29       Impact factor: 4.164

7.  Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews
Journal:  Diabetes Care       Date:  2015-01       Impact factor: 19.112

8.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

9.  Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.

Authors:  Anthony H Barnett; Stephen C Bain; Paul Bouter; Bengt Karlberg; Sten Madsbad; Jak Jervell; Jukka Mustonen
Journal:  N Engl J Med       Date:  2004-10-31       Impact factor: 91.245

10.  Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release.

Authors:  Otto Kamp; Marco Metra; Silvia Bugatti; Luca Bettari; Alessandra Dei Cas; Natalia Petrini; Livio Dei Cas
Journal:  Drugs       Date:  2010       Impact factor: 9.546

View more
  4 in total

1.  N-acetylcysteine attenuates myocardial dysfunction and postischemic injury by restoring caveolin-3/eNOS signaling in diabetic rats.

Authors:  Wating Su; Yuan Zhang; Qiongxia Zhang; Jinjin Xu; Liying Zhan; Qiqi Zhu; Qingquan Lian; Huimin Liu; Zhong-Yuan Xia; Zhengyuan Xia; Shaoqing Lei
Journal:  Cardiovasc Diabetol       Date:  2016-10-12       Impact factor: 9.951

2.  Mechanisms underlying diabetic cardiomyopathy: From pathophysiology to novel therapeutic targets.

Authors:  Shuo Cong; Chrishan J A Ramachandra; Kp Myu Mai Ja; Jonathan Yap; Winston Shim; Lai Wei; Derek J Hausenloy
Journal:  Cond Med       Date:  2020-05-05

3.  Empagliflozin Ammeliorates High Glucose Induced-Cardiac Dysfuntion in Human iPSC-Derived Cardiomyocytes.

Authors:  Kwong-Man Ng; Yee-Man Lau; Vidhu Dhandhania; Zhu-Jun Cai; Yee-Ki Lee; Wing-Hon Lai; Hung-Fat Tse; Chung-Wah Siu
Journal:  Sci Rep       Date:  2018-10-05       Impact factor: 4.379

4.  Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology.

Authors:  Christoph Maack; Michael Lehrke; Johannes Backs; Frank R Heinzel; Jean-Sebastien Hulot; Nikolaus Marx; Walter J Paulus; Patrick Rossignol; Heinrich Taegtmeyer; Johann Bauersachs; Antoni Bayes-Genis; Dirk Brutsaert; Heiko Bugger; Kieran Clarke; Francesco Cosentino; Gilles De Keulenaer; Alessandra Dei Cas; Arantxa González; Martin Huelsmann; Guido Iaccarino; Ida Gjervold Lunde; Alexander R Lyon; Piero Pollesello; Graham Rena; Niels P Riksen; Giuseppe Rosano; Bart Staels; Linda W van Laake; Christoph Wanner; Dimitrios Farmakis; Gerasimos Filippatos; Frank Ruschitzka; Petar Seferovic; Rudolf A de Boer; Stephane Heymans
Journal:  Eur Heart J       Date:  2018-12-21       Impact factor: 29.983

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.